Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine

Uzma N. Sarwar, Sandra Sitar, Julie E. Ledgerwood

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90% case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.

Original languageEnglish (US)
Pages (from-to)126-134
Number of pages9
JournalTravel Medicine and Infectious Disease
Volume9
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Marburgvirus
Travel Medicine
Ebolavirus
Disease Outbreaks
Filoviridae
Vaccines
Viral Hemorrhagic Fevers
Air Travel
Delivery of Health Care
Central Africa
Eastern Africa
Mortality
Epidemiology
Fever
Viruses
Infection

Keywords

  • Filovirus vaccines
  • Glycoprotein antigen
  • Imported Marburg infection

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health

Cite this

Filovirus emergence and vaccine development : A perspective for health care practitioners in travel medicine. / Sarwar, Uzma N.; Sitar, Sandra; Ledgerwood, Julie E.

In: Travel Medicine and Infectious Disease, Vol. 9, No. 3, 05.2011, p. 126-134.

Research output: Contribution to journalArticle

@article{8c18c5132e9041cfbf4d2cdf51d71ef6,
title = "Filovirus emergence and vaccine development: A perspective for health care practitioners in travel medicine",
abstract = "Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90{\%} case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.",
keywords = "Filovirus vaccines, Glycoprotein antigen, Imported Marburg infection",
author = "Sarwar, {Uzma N.} and Sandra Sitar and Ledgerwood, {Julie E.}",
year = "2011",
month = "5",
doi = "10.1016/j.tmaid.2010.05.003",
language = "English (US)",
volume = "9",
pages = "126--134",
journal = "Travel Medicine and Infectious Disease",
issn = "1477-8939",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Filovirus emergence and vaccine development

T2 - A perspective for health care practitioners in travel medicine

AU - Sarwar, Uzma N.

AU - Sitar, Sandra

AU - Ledgerwood, Julie E.

PY - 2011/5

Y1 - 2011/5

N2 - Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90% case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.

AB - Recent case reports of viral hemorrhagic fever in Europe and the United States have raised concerns about the possibility for increased importation of filoviruses to non-endemic areas. This emerging threat is concerning because of the increase in global air travel and the rise of tourism in central and eastern Africa and the greater dispersion of military troops to areas of infectious disease outbreaks. Marburg viruses (MARV) and Ebola viruses (EBOV) have been associated with outbreaks of severe hemorrhagic fever involving high mortality (25-90% case fatality rates). First recognized in 1967 and 1976 respectively, subtypes of MARV and EBOV are the only known viruses of the Filoviridae family, and are among the world's most virulent pathogens. This article focuses on information relevant for health care practitioners in travel medicine to include, the epidemiology and clinical features of filovirus infection and efforts toward development of a filovirus vaccine.

KW - Filovirus vaccines

KW - Glycoprotein antigen

KW - Imported Marburg infection

UR - http://www.scopus.com/inward/record.url?scp=79958849357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958849357&partnerID=8YFLogxK

U2 - 10.1016/j.tmaid.2010.05.003

DO - 10.1016/j.tmaid.2010.05.003

M3 - Article

C2 - 21208830

AN - SCOPUS:79958849357

VL - 9

SP - 126

EP - 134

JO - Travel Medicine and Infectious Disease

JF - Travel Medicine and Infectious Disease

SN - 1477-8939

IS - 3

ER -